Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript

James Gruber: Sure. Yes, since Q3 was a big turning point for us, positive operating cash flow, we do expect that to continue in normal first quarter seasonality. We mentioned in the remarks that we do — with the significant growth of ALKINDI SPRINKLE. We will have milestone payment in Q1 and with normal kind of seasonality issues in the beginning of the year, but we do expect positive operating cash flow outside of that going forward, certainly for full year 2024.

David Krempa: Second question, what’s your expectation for 2024 revenue and earnings?

James Gruber: We still expect revenue to be up — product revenue to be up significantly over 2023. We won’t be giving any detailed guidance on 2024 at this time. But when we report Q4 earnings, we’ll have — we’ll provide more guidance on full year 2024.

David Krempa: That’s the end of the e-mailed questions. Thank you, everyone, for joining us for our third quarter earnings.

Operator: Thanks, everyone, for the participation in today’s conference. It does conclude the program. You may now disconnect. Have a good evening.